Navigation Links
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Date:8/30/2007

hospital setting. The company currently has two Phase III products in development, including IV acetaminophen, for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence, visit http://www.cadencepharm.com.

Forward-Looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding: the timing for completing enrollment and disclosing results from Cadence's clinical trials of IV acetaminophen; the potential for submitting an NDA for IV acetaminophen and the timing for any such submission; the ability of IV acetaminophen to meet a significant unmet medical need; and the market potential for IV acetaminophen. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: delays in the initiation or completion of enrollment in the company's ongoing or planned clinical trials; the adequacy of the clinical trial design to support regulatory approvals in the stated indications or at all, and the possibility that additional clinical trials or preclinical studies may be required to support regulatory approvals; unexpected adverse side effects or inadequate therapeutic efficacy of IV acetaminophen that could delay or prevent its regulatory approval or commercialization, result in recalls or product liability claims, or diminish its market acceptance; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for IV acetami
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reaching a critical milestone in the ... of Boards of Pharmacy ® (NABP ® ) ... has passed the Internet Corporation for Assigned Names and ... .PHARMACY gTLD by the end of 2013, and will ... and related entities that are located in ...
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... de 2013 La junta directiva de ... OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, han ... Mayer, un ejecutivo ortopédico experimentado, será vicepresidente de ... , un experto refutado en dispositivos médicos, ... unirse a OSI como presidente de la junta, ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and the ... Community Wellness Fair to educate the public on health initiatives ... on Wednesday, May 22, 2013 from 4:00 pm until 7:00 ... Mallard Creek Road, Charlotte, NC 29262). , Medic, ... Mecklenburg County Department of Social Services are working ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
... 4 Formerly conjoined twins,Yurelia and Fiorella Rocha-Arias ... are now home in Costa Rica. According to ... (30) and went,to Southern California to visit Mending ... trip. Today (4), they flew home,to San Jose, ...
... (Nasdaq: MLNM ) today announced that its ... will be webcast live and may be,accessed by ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ), ... the Company, VELCADE(R),(bortezomib) for Injection, other product candidates ...
... attractions when swallowed by kids, new report shows. , , MONDAY, ... a little boy who swallowed a magnet and wound up ... Jose, Calif., swallowed two tiny magnets from his older brother,s ... the first ingestion, he confessed to his mom, Jill Eberle, ...
... budget for fiscal year 2009, if enacted, would spell ... national effort to respond to the HIV/AIDS epidemic in ... flat-funds critical federal support for research at the National ... Centers for Disease Control and Prevention (CDC), and vital ...
... ... and Commit(R), PITTSBURGH, Feb. 4 GlaxoSmithKline ... cessation products in January 2008, which includes NicoDerm CQ,patches, Nicorette gum, and ... try and quit, unfortunately, many of them fail,without the proper tools and ...
... Costs, WASHINGTON, Feb. 4 The Pharmaceutical ... response to,the Federal Trade Commission,s (FTC) recent opposition ... corporate health care providers in,Puerto Rico to collectively ... comment from the FTC highlights the agency,s consistent,opposition ...
Cached Medicine News:Health News:Formerly Conjoined Twins Leave Packard Children's Hospital; Heading Home to Costa Rica 2Health News:BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation 2Health News:Toy Magnets Can be a Very Real Threat 2Health News:Toy Magnets Can be a Very Real Threat 3Health News:2009 Bush budget a disaster for HIV/AIDS 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 3
5 mm concave jaws, cross action....
... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...
... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
Medicine Products: